Fusion Pharmaceuticals Enters Into Exclusive Worldwide License Agreement With Heidelberg University And Euratom For Actinium-Based PSMA Targeted Radiotherapy
Portfolio Pulse from Benzinga Newsdesk
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom for the development and commercialization of FPI-2265, a PSMA targeted radiotherapy for PSMA-expressing cancers. The agreement also settles a patent dispute. Fusion plans to provide updates on the TATCIST study in April and initiate a Phase 2/3 study in Q2 2024. The company has aligned with the FDA on the Phase 2/3 protocol for FPI-2265 and will pay the Licensors €1.0 million upfront, plus future royalties.
February 16, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fusion Pharmaceuticals Inc. has secured an exclusive license for FPI-2265, aiming to be the first approved PSMA targeted alpha therapy, and settled a patent dispute. The company is preparing for significant clinical milestones in 2024.
Securing an exclusive worldwide license for a potentially first-in-class treatment like FPI-2265 positions Fusion Pharmaceuticals in a favorable spot within the oncology sector. The settlement of the patent dispute removes a significant legal hurdle, potentially boosting investor confidence. The anticipation of clinical study updates and the initiation of a Phase 2/3 study in 2024 are likely to generate positive sentiment among investors, contributing to a bullish outlook for FUSN in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100